# advanced non-small-cell lung cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/advanced-non-small-cell-lung-cancer

> 6 upcoming FDA catalysts in advanced non-small-cell lung cancer: fianlimab (REGN) on Sep to Dec 2027 (topline data readout); fianlimab (REGN) on September 2027 (primary completion); domvanalimab (GILD) on December 2027 (primary completion); domvanalimab (GILD) on Dec 2027 to Mar 2028 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| 1H 2025 | [Taxotere (docetaxel) topline data readout](https://sec-api.dev/pdufa/docetaxel) | ANAB | advanced non-small-cell lung cancer | scheduled | "GSK is conducting a Phase 3 trial, COSTAR Lung, which is a randomized, open label 3-arm trial comparing cobolimab plus dostarlimab plus docetaxel to dostarlimab plus docetaxel to docetaxel alone in patients with advanced non-small-cell lung cancer ("NSCLC") who have progressed on prior anti-PD-(L)1 therapy and chemotherapy with top-line results expected in the first half of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1370053/000137005325000046/anab-20250331.htm)) |
| June 13, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Advanced Non-Small Cell Lung Cancer | completed | "NCT03516981 (A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-13 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03516981)) |
| June 8, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Advanced Non-Small Cell Lung Cancer | completed | "NCT03516981 (A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-13 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03516981?tab=results)) |
| Sep to Dec 2027 | [Fianlimab topline data readout](https://sec-api.dev/pdufa/fianlimab) | REGN | Advanced Non-Small Cell Lung Cancer | scheduled | "NCT05785767 (A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05785767)) |
| September 2027 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Advanced Non-Small Cell Lung Cancer | scheduled | "NCT05785767 (A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05785767)) |
| December 2027 | [Domvanalimab primary completion](https://sec-api.dev/pdufa/domvanalimab) | GILD | Advanced Non-Small Cell Lung Cancer | scheduled | "NCT05676931 (Study With Various Immunotherapy Treatments in Participants With Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05676931)) |
| Dec 2027 to Mar 2028 | [Domvanalimab topline data readout](https://sec-api.dev/pdufa/domvanalimab) | GILD | Advanced Non-Small Cell Lung Cancer | scheduled | "NCT05676931 (Study With Various Immunotherapy Treatments in Participants With Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05676931)) |
| Jan to Apr 2028 | [BNT116 topline data readout](https://sec-api.dev/pdufa/bnt116) | REGN | Advanced Non-Small Cell Lung Cancer | scheduled | "NCT05557591 (A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-01-26 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05557591)) |
| January 2028 | [BNT116 primary completion](https://sec-api.dev/pdufa/bnt116) | REGN | Advanced Non-Small Cell Lung Cancer | scheduled | "NCT05557591 (A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-01-26 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05557591)) |

## Drugs

- [Taxotere (docetaxel)](https://sec-api.dev/pdufa/docetaxel) (OTLC)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [Fianlimab](https://sec-api.dev/pdufa/fianlimab) (REGN)
- [Domvanalimab](https://sec-api.dev/pdufa/domvanalimab) (RCUS)
- [BNT116](https://sec-api.dev/pdufa/bnt116) (REGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/advanced-non-small-cell-lung-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "advanced non-small-cell lung cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/advanced-non-small-cell-lung-cancer

```bibtex
@misc{secapidev_indications_advanced_non_small_cell_lung_cancer_20261116,
  title        = {advanced non-small-cell lung cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/advanced-non-small-cell-lung-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_advanced_non_small_cell_lung_cancer_20261116","title":"advanced non-small-cell lung cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/advanced-non-small-cell-lung-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
